Daily Management Review

Pfizer Inc. Acquired Bamboo Therapeutics Inc. For ‘$645 Million’


The acquisition of Bamboo can boost Pfizer’s gene therapy investment agenda.

Bamboo Therapeutics Inc, a “privately held gene therapy developer”, has now been acquired by Pfizer Inc, whereby the deal was worth “$645 million”. The said acquisition was made by Pfizer in an attempt to enhance the company’s presence in the field of treating “rare diseases”. Even thought the research area concerning “gene therapy” dates back to a “quarter of a century”, it has nevertheless suffered “multiple setbacks” while the chief draw backs have been “safety concerns”.
The method of gene therapy aims to introduce “corrective genes” in the place of “malfunctioning cells”. Recently, better ways to gene replacements have been discovered, thanks to which the said field is earning an optimistic future potential.
While, the “Food and Drug Administration” of the United States yet withholds from approving any “gene therapies”, Europe, however, has passed two such treatments: “a treatment from GlaxoSmithKline for a rare immune disorder in babies and one from uniQure NV for a serious blood condition”.
The company of Bamboo started in the year of 2014 for taking Dr. Richard Jude Samulski’s work into advanced stage. Dr. Richard Jude Samulski is regarded as a “pioneer” in the field of gene therapy for he was the first one to recognise the “potential of using adeno-associated virus's (AAV) as a vehicle to replace a defective gene with a healthy gene”.
The acquisition has allowed Pfizer an access into “Bamboo's experimental gene therapies” taht deal with various rare diseases like “Duchenne Muscular Dystrophy (DMD), giant axonal neuropathy (GAN), Friedreich ataxia (FA) and Canavan disease”. Moreover, Reuters reports:
“Focused on neurological and neuromuscular diseases, Bamboo's drugs are still in the preclinical or early stages of development. Pfizer is paying the Chapel Hill, North Carolina-based company $150 million upfront, and Bamboo stands to make $495 million in milestone payments”.
Gene therapies are viewed as “one-time cure for intractable and expensive-to-treat diseases”, whereby Pfizer have an investor in the said field. Likewise, along other ventures of Pfizer, in the year of 2014, it entered into a partnership with “Spark Therapeutics Inc” that is based out of Philadelphia. The said collaboration sought to “develop SPK-9001, a gene therapy for hemophilia B”.

Science & Technology

With China Set To Dominate, 1 Billion Could Be Using 5G By 2023

Deutsche Telekom unveils next gen 5G mobile antennas in Europe

Diamonds are now the new gold

Expert Body Says Driving In A Driverless Car In An Inebriated Condition Or On Drugs Should Be Legalized

SEC’s EDGAR database vulnerable to cyber threats

Research Says The Risk Of Severe Turbulence On Planes Will Increase Due To Climate Change

Barclays and CLS Group aim to replace SWIFT with blockchain

Designing Of Cars Being Done With Hologram Goggles At Ford

The Already Surging Cyber Attacks Are Set To Rise Even Further, Says A Study

Chinese to equip smartphones with OLED displays

World Politics

World & Politics

Scholar Says Political Appointees Not As Important As Financial Ones In China For The Economy

An Expected Change In Brussels Could Be Crucial For The Euro Zone

Destroying People Who Wouldn't Help One Of His Bankrupt Businesses Was All Trump Talked About When He Met Him In 1990s: Branson

Russia Is Worried About America’s Unpredictability

No oil contracts with Iraqi Kurdistan: Iraq’s oil ministry

Donald Trump lost $ 600 million during his presidency

Britain puts its weight behind Europe in the battle between Boeing and Bombardier

EU hopes to keep the Iran nuclear deal afloat